Skylake–Crescendo consortium to acquire 20.7% of Medipost for KRW 140bn
- Deal value
- $97m
- Stake
- 20.7%
- Implied 100%
- $466m
- Revenue
- $38m
- Op. income
- -$4m
- Multiples
- PSR 12.3x
Deal value ÷ stake (structure unconfirmed)
2021 연결 · DART-verified
2021 연결 · DART-verified
On implied equity value
DART 20220321001536
- Target
- Medipost · Stem-cell therapeutics and cord blood banking
- Buyer
- Skylake–Crescendo consortium · FI
- Seller
- CEO Yang Yoon-sun (partial) plus new shares/CB
- Structure
- —
- Announced
- Mar 17, 2022
- Closed
- —
- Stage
- Signed
Target
Medipost, based in Pangyo, is a stem-cell therapy company that has sold Cartistem, the first allogeneic cord-blood-derived knee cartilage treatment, since 2012, and holds about 70% of Korea's cord blood banking market. It posted 2021 revenue of KRW 54.9bn and an operating loss of KRW 5.2bn.
Deal rationale
Medipost said the financing secured a largest shareholder able to actively support overseas business, with proceeds for a North American cell and gene therapy CDMO investment (KRW 85bn) and US trials of Cartistem and SMUP-IA-01 (KRW 55bn) (Dailypharm, Seoul Economic Daily). Skylake said it invested considering synergy with and growth of the fast-growing global CGT CDMO business; Crescendo cited its overseas growth experience and US network to help Medipost expand globally. The structure comprised 400,000 old shares for KRW 20bn, a KRW 70bn third-party rights issue and KRW 70bn of CBs.
| Revenue | $38m |
| Operating income | -$4m |
| EBITDA | — |
| Net income | — |
2021 연결 · DART-verified · 20220321001536
Press coverage
- 서울경제 (2022-03-17): “총 1400억 원 규모의 투자계약을 체결했다고 17일 밝혔다.”
- 한국경제 (2025-10-15): “2118억원을 투입해 메디포스트 지분 46%를 인수하며 공동 최대주주에”
- 데일리팜 (2022-03-17): “빠르게 성장하는 글로벌 세포유전자치료제 CDMO 사업과의 시너지와 성장성을 감안해 투자를 결정했다”
- 이투데이 (2022-02-14): “2021년 매출액 549억 원을 기록해 전년 대비 12.8% 증가”
This is a data entry summarising filings and press reports. Please check the original sources for the figures.